MZMinghui Zhu

Minghui Zhu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Minghui Zhu has a total of 36 co-authors. Here are the top co-authors by number of shared publications:

  • Qiang Zhu

    Department of Respiratory Medicine Chinese People's Liberation Army General Hospital Beijing China

    4 shared publications
  • Zhen Yang

    Department of Respiratory Medicine Chinese People's Liberation Army General Hospital Beijing China

    4 shared publications
  • Zhixin Liang

    Department of Respiratory and Critical Care Medicine, First Medical Center, Chinese PLA General Hospital

    4 shared publications
  • Zhuo Yang

    College of Medicine, Nankai University, Tianjin, China

    4 shared publications
  • Chunhua Liu

    School of Medicine, State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Bioactive Materials for Ministry of Education, Nankai University, Tianjin 300071, China

    3 shared publications
  • Xuan Qin

    School of Medicine, State Key Laboratory of Medicinal Chemical Biology, Key Laboratory of Tumor Microenvironment and Neuro-vascular Regulation, Nankai University, Tianjin 300071, China

    3 shared publications

Latest Publications

  • Open Access

    Predicting Ki‐67 labeling index level in early‐stage lung adenocarcinomas manifesting as ground‐glass opacity nodules using intra‐nodular and peri‐nodular radiomic features

    by Minghui Zhu, Zhen Yang, Wei Zhao, Miaoyu Wang, Wenjia Shi, Zhenshun Cheng, Cheng Ye, Qiang Zhu, Lu Liu, Zhixin Liang, et al.

    Objectives: To explore the diagnostic value of radiomics in differentiating between lung adenocarcinomas appearing as ground‐glass opacity nodules (GGO) with high‐ and low Ki‐67 expression levels.Materials and Methods: From January 2018 to January 2021, patients with pulmonary GGO who received lung resection were evaluated for potential enrollment. The included GGOs were then randomly divided into a training cohort and a validation cohort with a ratio of 7:3. Logistic regression (LR), decision tree (DT), support vector machines (SVM), and adaboost (AB) were applied for radiomic model construction. Area under the curve (AUC) of the receiver operating characteristic (ROC) curve was used to evaluate the diagnostic efficacy of the established models.Results: Seven hundred and sixty‐nine patients with 769 GGOs were included in this study. Two hundred and forty‐five GGOs were confirmed to be of high Ki‐67 labeling index (LI). In the training cohort, gender, age, spiculation sign, pleural indentation sign, bubble sign, and maximum 2D diameter of the nodule were found to be significantly different between high‐ and low Ki‐67 LI groups (p < 0.05), and spiculation sign and maximum 2D diameter of the nodule were further confirmed to be risk factors for Ki‐67 LI. The radiomic model established using SVM exhibited an AUC of 0.731 in the validation cohort, which was higher than that of the clinical‐radiographic model (AUC = 0.675). Moreover, radiomic model combining both intra‐ and peri‐nodular features showed better diagnostic efficacy than using intra‐nodular features alone (AUC = 0.731 and 0.720, respectively).Conclusions: The established radiomic model exhibited good diagnostic efficacy in differentiating between lung adenocarcinoma GGOs with high and low Ki‐67 LI, which was higher than the clinical‐radiographic model. Peri‐nodular radiomic features showed added benefits to the radiomic model. As a novel noninvasive method, radiomics have the potential to be applied in the preliminary classification of Ki‐67 expression level in lung adenocarcinoma GGOs.


  • Epidemiology and microbiology of Gram-negative bloodstream infections in a tertiary-care hospital in Beijing, China: a 9-year retrospective study

    by Qiang Zhu, Minghui Zhu, Chunyan Li, Lina Li, Mingxue Guo, Zhen Yang, Zhaorui Zhang, Zhixin Liang

    Background: Gram-negative bacterial bloodstream infections (BSIs) are associated with high morbidity and mortality. The present study examines the incidence, clinical characteristics, microbiological features, drug resistance and mortality associated with Gram-negative bacterial BSIs at a tertiary-care hospital in Beijing, China. Methods: This retrospective cohort study of patients with Gram-negative bacterial BSIs was performed between January 1, 2010, and December 31, 2018, at the Chinese People,s Liberation Army General Hospital. Results: A total of 6867 episodes of Gram-negative bacterial BSIs occurred among 3199 patients over 9 years. The overall incidence of Gram-negative bacterial BSIs fluctuated from 2.30 to 2.55 episodes per 1000 admissions over 9 years. Escherichia coli were the major pathogen (34.3%). The antibiotic resistance of ESBLs-producing E. coli was higher than non-ESBLs producing E. coli including the majority of antibiotics, but to carbapenems (0.7% VS 5.1%). Between 2010 and 2018, the overall mortality of Gram-negative bacterial BSIs decreased from 11.41% to 9.05% (X2=6.95, P=0.434). Conclusions: Cephalosporins and carbapenem antibiotics wereconsidered as the optimal treatment for patients with Gram-negative bacterial BSIs except for A. baumannii, which was treated according to the drug sensitivity or multidrug combination.


  • The efficacy and safety of low-frequency rotating static magnetic field therapy combined with chemotherapy on advanced lung cancer patients: a randomized, double-blinded, controlled clinical trial

    by Minghui Zhu, Zhen Yang, Hang Yu, Qiang Zhu, Yang Xu, Yanran Li, Chunyan Li, Wei Zhao, Zhixin Liang, Liangan Chen

    Purpose: To evaluate the efficacy and safety of magnetic field (MF) therapy by a randomized, double-blinded, controlled clinical trial. Materials and Methods: From February 2016 to August 2019, patients with advanced lung cancer who conformed to inclusion criteria were enrolled in this study. Patients were assigned into MF therapy group (MF group, receiving both MF therapy and chemotherapy) and control group (CON group, receiving sham MF therapy and chemotherapy) randomly. The treatment course was 21 days and 2 hours per day. Changes of life quality assessment scales, objective response rate (ORR) and disease control rate (DCR) were analyzed as primary end points. The secondary end points were progression-free survival (PFS), change of blood cytokine concentrations and safety. This study has been registered on Clinicaltrials.gov (ID: NCT02701231). Results: 77 patients were enrolled and 60 finished the study. Comparing to CON group, more patients in MF group (66.7% vs 25.9%) were experiencing life quality improvement on day 21. Besides, MF group patients had higher concentrations of IP-10 and GM-CSF, and lower concentration of sTREM-1 in plasma. However, the two groups were having similar ORR, DCR and PFS after treatment. Moreover, MF treatment did not increase adverse events in MF group. Conclusions: MF therapy could improve life quality and modulate blood cytokine concentration in advanced lung cancer patients. Hence, it might be applied as an adjuvant therapy along with chemotherapy.


  • Open Access

    Clinical characteristics of patients with Ochrobactrum anthropi bloodstream infection in a Chinese tertiary-care hospital: A 7-year study

    by Minghui Zhu, Xiaoyan Zhao, Qiang Zhu, Zhaorui Zhang, Yu Dai, Liangan Chen, Zhixin Liang


  • Open Access

    Epidemiology and microbiology of Gram-positive bloodstream infections in a tertiary-care hospital in Beijing, China: a 6-year retrospective study

    by Qiang Zhu, Yan Yue, Lichen Zhu, Jiewei Cui, Minghui Zhu, Liangan Chen, Zhen Yang, Zhixin Liang

    Background: Gram-positive bacterial bloodstream infections (BSIs) are serious diseases associated with high morbidity and mortality. The following study examines the incidence, clinical characteristics and microbiological features, drug resistance situations and mortality associated with Gram-positive BSIs at a large Chinese tertiary-care hospital in Beijing, China. Methods: A retrospective cohort study of patients with Gram-positive BSIs was performed between January 1, 2011, and June 31, 2017, at the Chinese People’s Liberation Army General Hospital. The patients’ data were collected and included in the reviewing electronic medical records. Results: A total of 6887 episodes of Gram-positive BSIs occurred among 4275 patients over 6 years, and there were 3438 significant BSI episodes 69% of these cases were healthcare-associated, while 31% were community-associated. The overall incidence of Gram-positive BSIs fluctuated from 7.26 to 4.63 episodes per 1000 admissions over 6 years. Malignancy was the most common comorbidity and indwelling central intravenous catheter was the most common predisposing factor for BSI. Staphylococci were the major pathogen (65.5%), followed by Enterococcus spp:(17.5%), Streptococcus spp.(7.1%) and other bacterial pathogens (9.9%). The resistance rates of Staphylococci and E.faecium to penicillins were more than 90%. the vancomycin-resistant isolates were E. faecium (4.1%) and staphylococcus epidermidis (0.13%); and only E.faecalis and E.faecium showed resistance to linezolid (3.8% and 3.1%). Between 2011 and 2017, the overall mortality of Gram-positive BSIs decreased from 6.27 to 4.75% (X2 = 0.912, p = 0.892). Neverthess, the mortality in the ICU decreased from 60.46 to 47.82%, while in the general ward it increased from 39.54 to 52.18%. Conclusions: The morbidity and mortality of Gram-positive BSIs have showed downward trends. Vancomycin and linezolid are still consider the best treatment for patients with Gram-positive BSIs.


  • Open Access

    Network analysis of microRNAs, genes and their regulation in human bladder cancer

    by Yang Li, Zhiwen Xu, Kunhao Wang, Ning Wang, Minghui Zhu

    Bladder cancer (BC) is the fifth most common malignancy occurring worldwide and a significant cause of cancer‑related morbidity and mortality. Although BC is a serious health issue, studies available concerning the relationship of genes, microRNAs (miRNAs) and their host genes has been lacking. In the present study, we assessed experimentally validated data from various sources that reported the effect of miRNA on various diseases, miRNA targeting of mRNAs, and combined these data with initial transcription factor (TF) binding site predictions within miRNA promoter regions. Topology networks obtained in this study included the differentially expressed, BC‑associated and global networks. The three networks may be used to assess the effect of miRNAs and their regulation in human BC. By comparing and analyzing the similarities and differences among the three networks, key nodes with the largest potential of affecting the behavior of a particular network were identified. The results also showed potentially substantially influential miRNAs and TFs, which revealed subnetworks demonstrating the mechanisms involved as well as regulatory miRNA network motifs in human BC. Regulatory pathways regarding differentially expressed elements, such as genes and miRNAs, demonstrate self‑adapting associations including, self‑adapting associations and feedback loops in genes MYC, TP53, PTEN and 10 differentially expressed miRNAs. The differentially expressed network partially identified the BC mechanism. miRNA‑targeted human BC genes were also enriched in highly relevant pathways, cell cycle regulation and apoptosis. The present study systematically delineated the pathogenesis of BC and provided theoretical foundations for gene therapy investigators to focu attention on key genes and miRNAs in future studies.